Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Tecentriq

Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1 200 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 20–21

HOS-135673 · Präparat HOS-097762

20  Atezolizumab monotherapy Atezolizumab in combination therapy Common colitisv, abdominal pain, dysphagia, stomatitis, dysgeusia, colitisv oropharyngeal painw, dry mouth Uncommon pancreatitisx Rare coeliac disease coeliac disease Hepatobiliary disorders Common AST increased, ALT increased, AST increased, ALT increased hepatitisy Skin and subcutaneous tissue disorders Very common rashz, pruritus rashz, pruritus, alopeciaah Common dry skinap Uncommon severe cutaneous adverse reactionsak, severe cutaneous adverse reactionsak, psoriasisan, lichen disordersaq psoriasisan Rare pemphigoid pemphigoid, lichen disordersaq Musculoskeletal and connective tissue disorders Very common arthralgia, back pain arthralgia, musculoskeletal painaa, back pain Common musculoskeletal painaa, arthritisat arthritisat Uncommon myositisab, tenosynovitisau tenosynovitisau Renal and urinary disorders Common blood creatinine increasedc proteinuriaac, blood creatinine increasedc Uncommon nephritisad Not known cystitis noninfectiveal General disorders and administration site conditions Very common pyrexia, fatigue, asthenia pyrexia, fatigue, asthenia, oedema peripheral Common influenza like illness, chills Investigations Common gamma-glutamyl transferase blood alkaline phosphatase increased, increased gamma-glutamyl transferase increased Uncommon blood creatine phosphokinase increased

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.